BCHE and Alzheimer disease: The 24-week multicenter (12 study centers across France), double-blind, randomized, placebo-controlled, parallel-group, phase II study by Piette et al., 2011 [37] investigated the efficacy of masitinib as an adjunct to a cholinesterase inhibitor and/or memantine, thus using an appropriate study design, and recruiting patients affected by mild-to-moderate AD.